Oral Ketamine for PTSD: 2025 Pilot Study Offers an Early Signal, Not a Final Answer

A 2025 pilot study explored low-dose oral ketamine for post-traumatic stress disorder, adding an early clinical signal to research on alternatives to infusion-based treatment. The study, known as OKTOP, was published online in European Neuropsychopharmacology on January 28, 2025. Its title identifies it as an open-label pilot, a limitation that is essential to interpreting the results. Read the publication record.

What the pilot explored

The research came from investigators associated with the University of the Sunshine Coast’s National PTSD Research Centre and collaborating institutions. According to the university’s account, the study explored feasibility, safety, and tolerability of low-dose oral ketamine administered in a clinical setting. Treatment involved one oral ketamine session each week for six weeks. Read the university’s description of the protocol.

The treatment setting is a significant detail. This was not evidence that a person should obtain ketamine independently or assume an oral product can be used without assessment and monitoring. The setting described in the report was part of the intervention studied.

What was reported

The university reported that 73 percent of participants described PTSD symptom reductions of more than half one week after finishing treatment. At one month after the final dose, it reported that 59 percent remained below half their starting symptom level. These figures come from the institution’s public summary; the PubMed entry does not provide an abstract. See the source and timing of the reported percentages.

The timing should stay attached to the numbers. A result one week after treatment and a result one month later do not establish what happens over a year. Nor do symptom-reduction percentages automatically establish recovery, sustained remission, or improvement in every part of daily life.

Why open-label design matters

In an open-label trial, participants and investigators know which treatment is being administered. Without a blinded control comparison, the study cannot separate the medication’s specific contribution from expectations, clinical contact, symptom fluctuation, and other possible influences.

That does not make an early pilot useless. It means the question it can answer is narrower than whether oral ketamine is an established PTSD treatment. Its design can help guide further research while leaving efficacy questions unresolved. The publication itself labels the work a pilot rather than a definitive randomized trial. Read the study’s title and journal record.

Oral does not automatically mean equivalent

The study should not be interpreted as showing that oral ketamine is interchangeable with intravenous ketamine, intranasal esketamine, or every compounded product. Demonstrating equivalence would require an appropriate comparison; an open-label oral pilot does not provide one.

Similarly, describing a possible accessibility advantage is different from demonstrating lower total costs, better long-term outcomes, or fewer adverse effects than another route. Such claims need their own comparative evidence, rather than being inferred from the convenience of swallowing a medication.

This is not a new PTSD approval

Spravato’s January 2025 U.S. label covers adult treatment-resistant depression and a separate depressive-symptom indication involving acute suicidal ideation or behavior. It does not include PTSD. The oral pilot therefore should not be confused with a regulatory approval for PTSD treatment. Review Spravato’s approved indications.

For a patient who has both PTSD and depression, those diagnostic distinctions still matter. Evidence for treating one condition should not silently become proof of effectiveness for the other.

What stronger evidence would need to address

• Whether benefit exceeds an appropriate control treatment.
• How long improvements last after the treatment course.
• Which patients are most likely to benefit.
• How adverse effects are measured and reported.
• How the approach compares with other care options.

The OKTOP findings are best understood as hypothesis-generating: encouraging enough to study further, but not a basis for confident promises. Careful coverage can acknowledge the interest in an oral approach while keeping the trial’s open-label design, clinical setting, and short follow-up visible.

Sources

• PubMed: OKTOP pilot publication record
• European Neuropsychopharmacology: Study DOI
• University of the Sunshine Coast: Study summary
• FDA: Spravato indications